{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T10:32:40Z","timestamp":1773916360864,"version":"3.50.1"},"reference-count":96,"publisher":"Informa UK Limited","issue":"1","funder":[{"DOI":"10.13039\/501100005888","name":"the Medical University of Lodz","doi-asserted-by":"publisher","award":["503\/1-156-04\/503-11-001 to JF"],"award-info":[{"award-number":["503\/1-156-04\/503-11-001 to JF"]}],"id":[{"id":"10.13039\/501100005888","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2020,1,2]]},"DOI":"10.1080\/14656566.2019.1688784","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T14:57:17Z","timestamp":1573743437000},"page":"73-84","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":10,"title":["Recent advances in the pharmacological management of constipation predominant irritable bowel syndrome"],"prefix":"10.1080","volume":"21","author":[{"given":"Karolina","family":"Niewinna","sequence":"first","affiliation":[{"name":"Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9660-2158","authenticated-orcid":false,"given":"Anna","family":"Zieli\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakub","family":"Fichna","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2019,11,14]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.3906\/sag-1509-44"},{"issue":"24","key":"cit0002","first-page":"5751","volume":"21","author":"Manzoli L","year":"2017","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"7","key":"cit0003","first-page":"451","volume":"110","author":"Geijo-Mart\u00ednez F","year":"2018","journal-title":"Rev Esp Enfermedades Dig"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2018.08.006"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.02.029"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2017.41"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.explore.2018.09.003"},{"issue":"1","key":"cit0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13030-017-0120-x","volume":"12","author":"Kosako M","year":"2018","journal-title":"Biopsychosoc Med"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2018.1494571"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.5056\/jnm16214"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.3109\/00365529709011203"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1427733"},{"issue":"9","key":"cit0013","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/j.1365-2036.2010.04273.x","volume":"31","author":"Belsey J","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30023-1"},{"issue":"5","key":"cit0015","first-page":"385","volume":"3","author":"Gershon MD","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13459"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.09.031"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00726-8"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.5056\/jnm16220"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013562"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13167"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1007\/s12664-017-0757-1"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2014.195"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S174982"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/9624702"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0607358"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.02.054"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2011.241877"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2010.00882.x"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aal2171"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2016.1142532"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.04.020"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.05.006"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2017.09.028"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13469"},{"key":"cit0036","unstructured":"Marsh E, Morales W, Chua K, et al. Undefined. Lovastatin lactone inhibits methane production in human stool homogenates. content.stockpr.com [Internet]. 2015 [cited 2019 Jul 9]. Available from: http:\/\/content.stockpr.com\/syntheticbiologics\/db\/220\/608\/file\/Lovastatin+in+Human+Stool-FINAL+Poster+(ACG+2015).pdf"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i2.384"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.35394"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1159\/000356314"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-016-2821-1"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.40312.x"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-302167"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0111868"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1080\/00365520802321212"},{"key":"cit0045","unstructured":"Zelnorm single patient IND packet [Internet]. [cited 2019 Jul 14]. Available from: http:\/\/www.fda.gov\/AboutFDA\/ReportsManualsForms\/Forms\/default.htm"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.2147\/tcrm.2007.3.1.107"},{"key":"cit0047","unstructured":"NDA 021200 S015 Zelnorm (tegaserod) i NDA\/BLA multi-disciplinary review and evaluation [Internet]. [cited 2019 Jul 14]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/021200Orig1s015MultidisciplineR.pdf"},{"key":"cit0048","volume":"1","author":"Marciniak TA","year":"2019","journal-title":"Am J Ther"},{"key":"cit0049","unstructured":"FDA briefing document joint meeting of the gastrointestinal drugs advisory committee and drug safety and risk management advisory committees [Internet]. 2018 [cited 2019 Jul 13]. Available from: https:\/\/www.fda.gov\/media\/119011\/download"},{"key":"cit0050","unstructured":"FDA approves the reintroduction of ZelnormTM(tegaserod) for Irritable Bowel Syndrome with Constipation (IBS-C) in women under 65 [Internet]. [cited 2019 Apr 16]. Available from: https:\/\/www.prnewswire.com\/news-releases\/fda-approves-the-reintroduction-of-zelnorm-tegaserod-for-irritable-bowel-syndrome-with-constipation-ibs-c-in-women-under-65-300821611.html"},{"key":"cit0051","unstructured":"Drug approval package. [cited 2019 Apr 16]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2006\/021908s000_AmitizaTOC.cfm"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.4137\/CGast.S7625"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1177\/2040622314567678"},{"key":"cit0054","unstructured":"FDA approves linzess to treat certain cases of irritable bowel syndrome and constipation [Internet]. [cited 2019 Jul 13]. Available from: https:\/\/www.drugs.com\/newdrugs\/fda-approves-linzess-certain-cases-irritable-bowel-syndrome-constipation-3469.html"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.12"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0134349"},{"key":"cit0057","unstructured":"Synergy pharmaceuticals announces fda approval of trulance (plecanatide) for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adults [Internet]. [cited 2019 Jul 15]. Available from: https:\/\/www.drugs.com\/newdrugs\/synergy-pharmaceuticals-announces-fda-approval-trulance-plecanatide-irritable-bowel-syndrome-4685.html"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.2147\/CEG.S145668"},{"key":"cit0059","unstructured":"SYN-010 : synthetic biologics, Inc. (SYN) [Internet]. [cited 2019 Jul 15]. Available from: https:\/\/www.syntheticbiologics.com\/product-pipeline\/syn-010"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.8406.3"},{"key":"cit0061","unstructured":"A single-dose, open-label, study to evaluate the sustainability of the effects of SYN-010 in patients with IBS-C - full text view - clinicalTrials.gov [Internet]. [cited 2019 Apr 16]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02493036"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03870.x"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2010.01476.x"},{"key":"cit0064","unstructured":"NCT01056107 @ clinicaltrials.gov [Internet]. [cited 2019 Mar]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01056107?term=rose-010&cond=ibs&rank=1"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00076.2012"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2016.12.007"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.07.052"},{"key":"cit0068","unstructured":"NCT00912301 @ clinicaltrials.gov [Internet]. [cited 2019 Mar]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00912301?cond=sodium+chenodeoxycholate&rank=1"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15106"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007790"},{"key":"cit0071","unstructured":"A study to evaluate the safety and efficacy of RDX5791 for the treatment of constipation predominant irritable bowel syndrome (IBS-C) - full text view - clinicalTrials.gov [Internet]. [cited 2019 Jul 15]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01340053"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-017-0614-0"},{"key":"cit0073","unstructured":"The efficacy of AZD1722 in constipation predominant Irritable Bowel Syndrome (IBS-C) - full text view - clinicalTrials.gov [Internet]. [cited 2019 Jul 15]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01923428"},{"key":"cit0074","unstructured":"A 12-week study with a 4-week randomized withdrawal period to evaluate the efficacy and safety of tenapanor for the treatment of IBS-C - full text view - clinicaltrials.gov [Internet]. [cited 2019 Jul 15]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02621892"},{"key":"cit0075","unstructured":"A 26-week study to evaluate the efficacy and safety of tenapanor in IBS-C - full text view - clinicalTrials.gov [Internet]. [cited 2019 Jul 15]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02686138"},{"key":"cit0076","unstructured":"Ardelyx showcases new data from T3MPO-3 long-term safety trial of tenapanor for IBS-C in presidential poster at ACG 2018 annual meeting | Ardelyx, Inc. [Internet]. [cited 2019 Jul 13]. Available from: http:\/\/ir.ardelyx.com\/news-releases\/news-release-details\/ardelyx-showcases-new-data-t3mpo-3-long-term-safety-trial"},{"key":"cit0077","unstructured":"Ardelyx submits new drug application for tenapanor for IBS-C [Internet]. [cited 2019 Jul 13]. Available from: https:\/\/www.drugs.com\/nda\/tenapanor_180913.html"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.5056\/jnm.2014.20.1.6"},{"key":"cit0079","unstructured":"DDP733. [cited 2019 Jul 15]. Available from: https:\/\/www.drugbank.ca\/drugs\/DB05049"},{"issue":"5","key":"cit0080","first-page":"416","volume":"8","author":"Evangelista S","year":"2007","journal-title":"Curr Opin Invest Drugs"},{"key":"cit0081","unstructured":"Title: Compositions comprising MKC-733 (PUMOSETRAG) useful for treating irritable bowel syndrome [Internet]. 2008 [cited 2019 Apr 16]. Available from: https:\/\/www.lens.org\/images\/patent\/WO\/2008100422\/A1\/WO_2008_100422_A1.pdf"},{"key":"cit0082","unstructured":"A study to evaluate the safety, tolerability and pharmacodynamics of DDP733 for IBS-c - full text view - clinicaltrials.gov [Internet]. [cited 2019 Jul 15]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00215566"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4720-05.2006"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S53027"},{"key":"cit0085","doi-asserted-by":"crossref","unstructured":"Lim HC, Kim YG, Lim JH, et al. Effect of Itopride hydrochloride on the ileal and colonic motility in guinea pig in vitro. Yonsei Med J. 2019;49(3):472\u2013478.","DOI":"10.3349\/ymj.2008.49.3.472"},{"key":"cit0086","unstructured":"Study to evaluate the role of Itopride HCI in patients with irritable bowel syndrome with predominant constipation - full text view - clinicaltrials.gov [Internet]. [cited 2019 Jul 15]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01027260"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2007.06.033"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2014.12.002"},{"key":"cit0089","unstructured":"Proof-of-principle study of TC-6499 in the treatment of constipation predominant Irritable Bowel Syndrome (IBS) - full text view - clinicaltrials.gov [Internet]. [cited 2019 Jul 15]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01149200"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.070789"},{"key":"cit0091","unstructured":"ZelnormTM(tegaserod) [Internet]. 2018 [cited 2019 Jul 13]. Available from: https:\/\/www.fda.gov\/media\/119019\/download"},{"key":"cit0092","unstructured":"Kamuda JA, Candidate P, Mazzola N. Plecanatide (Trulance) for chronic idiopathic constipation and irritable bowel syndrome with constipation. P and T. 2018;43(4):207\u2013210."},{"key":"cit0093","unstructured":"Sodium-chenodeoxycholate @ pubchem.ncbi.nlm.nih.gov [Internet]. [cited 2019 Mar]. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Sodium-chenodeoxycholate#section=NLM-Curated-PubMed-Citations"},{"key":"cit0094","unstructured":"Important precautions. [cited 2019 Sep]. Available from: http:\/\/www.meppo.com\/pdf\/drugs\/2845-GANATON-1415104080.pdf. 4\u20136."},{"key":"cit0095","unstructured":"TC 6499 - AdisInsight [Internet]. [cited 2019 Oct 17]. Available from: https:\/\/adisinsight.springer.com\/drugs\/800027601"},{"key":"cit0096","unstructured":"Pumosetrag hydrochloride; www.chemscene.com [Internet]. [cited 2019 Sep]. Available from: https:\/\/www.chemscene.com\/194093-42-0.html"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2019.1688784","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T22:44:42Z","timestamp":1722033882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2019.1688784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,14]]},"references-count":96,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1,2]]}},"alternative-id":["10.1080\/14656566.2019.1688784"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2019.1688784","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-04-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}